SUZHOU, China, and HONG KONG – Despite investor worries over the long-term political and economic stability of Hong Kong after almost four months of social unrest and frequent violent protests, Chinese biotech executives remain optimistic about the outlook for the prospects for the market.

SUZHOU, China, and HONG KONG – Despite investor worries over the long-term political and economic stability of Hong Kong after almost four months of social unrest and frequent violent protests, Chinese biotech executives remain optimistic about the outlook for the prospects for the market.

HONG KONG – The new Shanghai Stock Exchange's Science and Technology Innovation board, officially launched in late July, marks China's boldest move yet to attract biopharma and technology companies to its often-turbulent financial markets.

HONG KONG – The new Shanghai Stock Exchange's Science and Technology Innovation board, officially launched in late July, marks China's boldest move yet to attract biopharma and technology companies to its often-turbulent financial markets.

HONG KONG – Sinomab Bioscience Ltd., a Hong Kong clinical-stage antibody firm, said its application for a Hong Kong IPO was accepted by the stock exchange, making it the 16th biopharma to submit an application under the new rules of the Hong Kong Exchange (HKEX).

HONG KONG – Sinomab Bioscience Ltd., a Hong Kong clinical-stage antibody firm, said its application for a Hong Kong IPO was accepted by the stock exchange, making it the 16th biopharma to submit an application under the new rules of the Hong Kong Exchange (HKEX).

The World Health Assembly, a decision-making body of the World Health Organization (WHO), included a chapter on Chinese traditional medicine in the latest version of its influential global compendium for the first time in history.

The World Health Assembly, a decision-making body of the World Health Organization (WHO), included a chapter on Chinese traditional medicine in the latest version of its influential global compendium for the first time in history.

HONG KONG – The biotech sector in greater China ended the financial year on a high note. Companies on the Hong Kong Stock Exchange reported better-than-expected results, including seven pre-revenue startups that went public over the last year, adding to the energy in the biotech space.